Veronese Nicola, Demurtas Jacopo, Soysal Pinar, Smith Lee, Torbahn Gabriel, Schoene Daniel, Schwingshackl Lukas, Sieber Cornel, Bauer Jurgen, Cesari Matteo, Bruyere Oliviere, Reginster Jean-Yves, Beaudart Charlotte, Cruz-Jentoft Alfonso J, Cooper Cyrus, Petrovic Mirko, Maggi Stefania
National Research Council, Neuroscience Institute, Aging Branch Via Giustiniani, 2, Padua, Italy.
Primary Care Department Azienda, USL Toscana Sud Est, Grosseto, Italy.
Eur Geriatr Med. 2019 Dec;10(6):853-862. doi: 10.1007/s41999-019-00233-w. Epub 2019 Sep 6.
The clinical relevance of sarcopenia has increasingly been recognized. However, whether it is associated with the development of other medical conditions is still unclear. Therefore, we aimed to capture the scale of outcomes that have been associated with the presence of sarcopenia and systematically assess the quality, strength, and credibility of these associations using an umbrella review methodology.
A systematic review in several databases was carried out, until 20th February 2019. For each association, random-effects summary effect size, 95% confidence intervals (CIs), heterogeneity (I), evidence for small-study effect, evidence for excess significance bias, and 95%-prediction intervals were estimated. We used these metrics to categorize the evidence of significant outcomes (p < 0.05) from class I (convincing) to class IV (weak), according to pre-established criteria.
From 358 abstracts, 6 meta-analyses with 14 associations were included. Sarcopenia was associated with higher risk of other comorbidities and mortality in 11 of 14 outcomes explored. However, only 3 outcomes (i.e., association between sarcopenia and increased risk of death in community-dwelling older people [odds ratio, OR = 3.60; 95% CI 2.96-4.37; n = 14,305], disability [OR = 3.04; 95% CI 1.80-5.12; n = 8569], and falls [OR = 1.60; 95% CI 1.31-1.97; n = 12,261]) presented a highly suggestive evidence (class II). Other association was classified as having only a weak evidence.
Sarcopenia is associated with several adverse health-related outcomes in older people, and its associations with mortality, disability, and falls are supported by a highly suggestive evidence. The effect of interventions on sarcopenia to improve these outcomes needs to be investigated.
肌肉减少症的临床相关性已越来越受到认可。然而,它是否与其他疾病的发生有关仍不清楚。因此,我们旨在梳理与肌肉减少症相关的一系列结局,并采用汇总分析方法系统评估这些关联的质量、强度和可信度。
截至2019年2月20日,在多个数据库中进行了系统评价。对于每一种关联,估计随机效应汇总效应大小、95%置信区间(CI)、异质性(I)、小研究效应证据、过度显著性偏差证据和95%预测区间。我们根据预先设定的标准,使用这些指标将显著结局(p < 0.05)的证据从I类(令人信服)到IV类(薄弱)进行分类。
从358篇摘要中,纳入了6项包含14种关联的荟萃分析。在探索的14种结局中的11种中,肌肉减少症与其他合并症和死亡风险较高相关。然而,只有3种结局(即社区居住老年人中肌肉减少症与死亡风险增加之间的关联[优势比,OR = 3.60;95%CI 2.96 - 4.37;n = 14,305]、残疾[OR = 3.04;95%CI 1.80 - 5.12;n = 8569]以及跌倒[OR = 1.60;95%CI 1.31 - 1.97;n = 12,261])呈现出高度提示性证据(II类)。其他关联被归类为仅有薄弱证据。
肌肉减少症与老年人的几种不良健康相关结局有关,其与死亡率、残疾和跌倒之间的关联得到了高度提示性证据的支持。需要研究针对肌肉减少症的干预措施对改善这些结局的效果。